Connect with us

Tech

Zoom Becomes the First Video Communications Client to Attain Common Criteria Certification

Published

on

SAN JOSE, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) — Zoom Video Communications, Inc. (NASDAQ:ZM) today announced that Zoom Meeting Client version 5.6.6 has become the first video communications client to attain certification for Common Criteria Evaluation Assurance Level 2 (v3.1 rev. 5), issued by the German Federal Office for Information Security (BSI).

Common Criteria is an international standard for objectively evaluating that an IT product satisfies a defined set of security requirements. The evaluation involves analyzing a specific set of security targets, including guidance documentation, architectural design, life cycle aspects, testing and vulnerability assessment. The Zoom Meeting Client v5.6.6 has been evaluated by the BSI against the Common Criteria standard and found to exhibit a clear chain of evidence that the process of specification, implementation, and evaluation has been conducted in a rigorous and standard manner.

Mutually recognized in more than 25 countries including the UK, US, Canada, and Germany, Common Criteria is regarded as a leading benchmark for IT product security certification. A growing number of users expect IT vendors to produce trusted and reliable evidence for the cybersecurity capabilities of their products.

“This Common Criteria certification represents a major milestone for Zoom,” said Jason Lee, Chief Information Security Officer at Zoom. “We’re the first video communications client to receive this important certification, reinforcing our commitment to our customers. Security and privacy are the cornerstones of everything we do, and we are continually innovating secure solutions for all users of our platform.”

At present, the BSI has certified Zoom version 5.6.6 for Windows, macOS, iOS, and Android. While version 5.6.6 was the version of Zoom client available at the time of the certification, we always recommend customers utilize the newest version of the client to take advantage of Zoom’s latest security updates and features.

“The Common Criteria certification is a global benchmark in cybersecurity,” said Sandro Amendola, Head of Standardization/Certification/Telecommunications Networks Security Department, BSI. “The Zoom client demonstrated a high security standard across its product, successfully completing one of the most demanding evaluation procedures a company can undertake.”

To learn more about Zoom’s Common Criteria certification, please visit the BSI website and the Zoom Trust Center.

About Zoom
Zoom is for you. We help you express ideas, connect to others, and build toward a future limited only by your imagination. Our frictionless communications platform is the only one that started with video as its foundation, and we have set the standard for innovation ever since. That is why we are an intuitive, scalable, and secure choice for individuals, small businesses, and large enterprises alike. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California. Visit zoom.com and follow @zoom.

Zoom Public Relations
Matt Nagel
press@zoom.us

Read More

Source Here: benzinga.com

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Tech

WHO Recommends Glaxo, Eli Lilly Drugs for COVID-19 Treatment Amid Omicron Surge

Published

on

Skip to main content

Share:

An expert panel at the World Health Organization (WHO) recommended the use of treatments developed by Eli Lilly And Co (NYSE: LLY) and GlaxoSmithKline Plc (NYSE: GSK) / Vir Biotechnology Inc (NASDAQ: VIR) for COVID-19 patients.

In its guidelines published in the British Medical Journal, the panel has recommended Lilly’s baricitinib (Olumiant), a Janus kinase (JAK) inhibitor, combined with corticosteroids for severe COVID-19 patients.
The panel also conditionally recommended sotrovimab, a monoclonal antibody developed by GSK / Vir, for patients with non-severe COVID-19 at the highest risk of hospitalization.
Related:WHO Recommends IL-6 Drugs From Sanofi, Roche For Critically-Ill COVID-19 Patients.
While the global body has already approved the monoclonal antibodies casirivimab with Imdevimab from Regeneron Pharmaceuticals Inc (NASDAQ: REGN), it has found insufficient data to recommend one treatment over another from that class of medications.
The panel also noted that the activity of these drugs against new variants of the virus, such as Omicron remained uncertain and said it would update the guidelines once new data are available.
Price Action: GSK shares are up 0.88% at $45.46, VIR shares are down 2.87% at $36.57, and LLY stock is down 1.59% at $245.69 during the market session on the last check Friday.

Related Articles (GSK + VIR)

GSK, Vir Biotech File For Emergency Use Nod For Intramuscular Sotrovimab For COVID-19

Vir Biotechnology Expands Partnership With Bill & Melinda Gates Foundation, Launches New Antibody Research Initiative Aimed At A Functional Cure For HIV And Prevention Of Malaria; Foundation Has Committed $40M Equity Investment And $10M Grant

Adagio’s COVID-19 Antibody Has Neutralizing Activity Comparable To Other Antibodies

20 Stocks Moving in Thursday’s Pre-Market Session

50 Biggest Movers From Yesterday

US To Purchase 600K Additional Doses of GSK-Vir’s COVID-19 Antibody Therapy

View the discussion thread.

Posted-In: Briefs COVID-19 CoronavirusBiotech Government News Health Care General

Read More

Source: benzinga.com

Continue Reading

Tech

ST Imaging’s ViewScan 4 Microfilm Scanner Wins 2022 Platinum Modern Library Award

Published

on

Northbrook, IL, Jan. 14, 2022 (GLOBE NEWSWIRE) — For an eighth straight year, ST Imaging’s ViewScan 4 microfilm scanner has been recognized for a Platinum Modern Library Awards (MLAs) from LibraryWorks. ST Imaging, a Digital Check brand, is a worldwide leader in the design and manufacturing of digital microfilm viewer/scanners, and the only microfilm scanner manufacturer to have continuously received the Platinum MLA for all eight years.

“We are thrilled to be recognized again as a leading microfilm scanner in the library market by librarians,” says Matt Anderson, Vice President of Sales and Marketing for ST Imaging. “We are dedicated to continue to develop and enhance the user experience of the ViewScan 4 and PerfectView software.”

When designing the ViewScan 4 and PerfectView software, we received direct feedback from the industry on how to implement those features and how to make them easy to use. The result is a simplified, color-coded, streamlined user experience that makes working with microfilm fast and fun. While older reader/printers and other microfilm scanners can be difficult to use, the ViewScan makes loading and scanning film quick, fun, and easy. The ViewScan also allows users to share their discoveries like never before.

At ST Imaging, we understand that most customers are not experts in the field of digital image capture. Our system describes our camera size as we expect most of our customers to understand it, as you would for a cellphone or digital camera. The ViewScan 4 is equipped with a native 18-megapixel image sensor. That means there are 18 million pixels capturing the focused light providing an image instantly to the monitor. Competitive scanners may use a different definition for their camera. Be sure you have accurate information of the image sensor on the camera in your microfilm scanner and if you have any doubt, request a side-by-side comparison.

Jenny Newman, publisher and MLA program manager said, “It’s great to see ST Imaging and their ViewScan 4 be recognized year after year as a leading microfilm scanner in the library market.”

The MLAs were created to recognize top products in the library industry in a truly unbiased format. Products were submitted by companies, collected by LibraryWorks which distributes them to their database of more than 80,000 librarians at public, K-12, academic, and special libraries. Only customers who have had experience with these products in their facilities were permitted to judge the products, resulting in a truly unbiased score.

About ST Imaging

ST Imaging is a leading worldwide manufacturer and distributor of micrographic equipment and other collection scanning solutions. Founded in 1989, the company was acquired in 1999 by Digital Check Corp. In 2004, ST Imaging introduced the revolutionary ST200 digital film scanner, changing the way library customers view film.

The company’s flagship product, the ViewScan film scanner set the standard for making film scanning easy and assessable to the public. ViewScan systems incorporate the latest technology to improve viewing, scanning, editing, and sharing of microfilm within libraries, schools, government, business, and other collections.

The ST Imaging headquarters and manufacturing are in Meridian, ID. Scanners are available through a worldwide network of authorized resellers and are supported by ST Imaging’s comprehensive fulfillment, training, support, warranty, and repair services.

About LibraryWorks

LibraryWorks helps administrators to make informed decisions about library technology, automation and software, collection development and management, facilities and furnishings, staffing, purchasing, and other areas that drive effective strategic planning and day-to-day operations. Our family of resources can enable you to identify best practices, monitor trends, evaluate new products and services, apply for grants and funding, post or find a job, and even enjoy some library humor.

About the Modern Library Awards program

The Modern Library Awards (MLAs) is a program designed to recognize elite products and services in the library market which can help library management personnel enhance the quality-of-experience for the library user and increase the performance of their library systems.

ViewScan 4 Microfilm Reader
Modern Library Awards

Matt Anderson
ST Imaging
208-514-4000
manderson@stimaging.com
Read More

Original Article: benzinga.com

Continue Reading

Tech

Vermont Lawmakers File Drug Decriminalization Bill, Here’s What’s in It

Published

on

It seems that Vermont is on its way to decriminalizing all drugs, as the state’s Democratic and Progressive lawmakers filed a new bill this week to decriminalize their possession.

Reps. Logan Nicoll (D) and Selene Colburn (P) introduced the legislation, which is seen as a harm reduction tool that can also help address racial disparities in enforcement, Marijuana Moment reported.

What’s In The New Bill?

The measure would make possession and distribution of personal-use amounts of currently illicit drugs punishable by a $50 fine – without a threat of a prison sentence or being subject to a substance use screening and health service.

In addition, if the amount of the drug in question is under a “benchmark personal use” threshold – previously set by a new Drug Use Standards Advisory Board – people would face a civil penalty once the bill amends the state statute on drug possession and distribution.

According to the new policy, the board would include “experts in the fields of general and behavioral health care, substance use disorder treatment, and drug user communities.”

Moreover, criminal penalties for sharing small amounts of currently illicit drugs without compensation would be removed.

So far, nearly one-third of the Vermont House, or 40 initial cosponsors, support the proposal.

Colburn told Marijuana Moment in an interview this week that the goal is to streamline the process of legalization in a way that lawmakers in other states have, citing Maine as an example.

The legislator said that she’s been “talking with a lot of frontline folks, a lot of people with lived experience, and the vast majority of those folks will share that justice system involvement has been a hurdle and a barrier in their recovery, or even just their access to life-saving medication or to harm reduction tools.”

Colburn added that in their discussions, she and her colleagues are trying to be clear that the vast majority of people who are drug users are not struggling with substance use disorder. “So this is definitely a civil liberties issue as well. But for folks who [do have substance misuse disorders], the impacts of criminalization have caused, and continue to cause, so much harm.”

Related News

Photo: Courtesy of Colin Davis on Unsplash

Read More

Source: benzinga.com

Continue Reading

Trending

BaypointNews.com